Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york
3
×
new york blog main
new york top stories
3
×
alnylam pharmaceuticals
amgen
inclisiran
pcsk9 inhibitors
regeneron pharmaceuticals
akcea therapeutics
alirocumab
anylam pharmaceuticals
biotech
cardiomyopathy
cholesterol
deals
drugs
evolocumab
fda
inotersen
neuropathy
novartis
onpattro
patisiran
pcsk9
pfizer
praluent
repatha
rna interference
san diego blog main
san diego top stories
sanofi
tafamidis
tegsedi
the medicines co.
What
drug
fda
3
×
medicines
3
×
cholesterol
medco
acquire
ago
agreed
akcea
alnylam
amyloidosis
approved
attr
available
battle
billion
bringing
brings
cash
clears
closer
company
compound
deal
debilitating
disease
filing
genetic
inched
lowering
market
morning
new
novartis
oks
patients
pfizer
phase
poised
positive
Language
unset
Current search:
fda
×
medicines
×
" new york top stories "
×
" new york "
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
